Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHWSL.L Regulatory News (HWSL)

  • There is currently no data for HWSL

Net Asset Value(s)

4 May 2020 09:24

RNS Number : 8033L
HWSI Realisation Fund Ltd
04 May 2020
 

 

HWSI Realisation Fund Limited

(the "Company")

Net Asset Value and Investment Update

 

NAV

The Company announces that the unaudited cum-income net asset value per Ordinary Share as at 31 March 2020 was 61.20 pence, after deducting the 19 pence per share capital distribution by way of B share issue and redemption that was announced on 31 March. The Ordinary Shares went ex the entitlement on 6 April. Prior to deducting the capital distribution the net asset value per Ordinary Share cum income would have been 80.20 pence.

Investment Update

Shareholders will recall that in the Company's announcement dated 27 March 2020, the Board, the Investment Manager and Hadrian's Wall Capital (the "Investment Adviser") acknowledged that Covid-19 was likely to have a detrimental effect on portfolio investments. The spread of Covid-19 and the associated impact on economic activity has led to significant volatility in both the equity and debt capital markets, as well as to other market indicators such as interest rates and forecast inflation. Whilst the net asset value as at 29 February 2020 was published at a much earlier stage of the pandemic, the situation remains fluid and it is the Investment Adviser's and the Board's view that it is not possible to estimate with any certainty the impact of Covid-19 on the portfolio at this time. Nevertheless, there have been a number of specific developments in the portfolio and a number of requests for forbearance have been received from the Company's borrowers.

Forbearance requests are being dealt with on a case-by-case basis. In each case the Investment Adviser is working closely with borrowers to:

1. Help them survive this pandemic and continue to be economically viable; and

 

2. Ensure that any forbearance tries to protect the full economic interest of the Company (both interest and capital protection)

 

At the date of this announcement, 10 Loans (representing a cumulative total of £71.1m of principal outstanding loan balances) have requested forbearance of some kind. The request for forbearance arrangements include, but not limited to:

· three months' deferred interest and capital payments,

· a proportional payment of interest due based on their actual collections as a percentage of expected collections,

· full interest on the deployed capital and a reduced rate of interest to be charged on the variable cash at bank in the borrower SPV.

 

All forbearance requests and agreements are being reviewed on a monthly basis or as extraordinary circumstances arise.

 

As a prudent measure, with very few exceptions, loans in the portfolio have had an increase in expected losses arising from a movement in the relevant risk category solely by virtue of the fact that Covid-19 will have to a greater or lesser extent, an impact on the Company's Loans and this has to be recognised. Eight borrowers have had their risk ratings downgraded or their Expected Loss adjusted to the full level of the Risk Category. In total the Expected Credit Loss provision has increased by £2.7m (equivalent to 1.9p per share) during the month bringing the aggregate Expected Loss provisions to £28.4m.

 

As new facts and information come to light as to the impact of Covid-19 on the Loans, the Board will review the need for any additional provisioning and will keep shareholders updated on material developments.

The Board, after due consideration and following recommendations from the Investment Adviser, has determined that the above changes to the IFRS9 provisions to reflect the developments in the portfolio, caused by the uncertainties associated with the COVID-19 pandemic, are prudent.

Other portfolio developments

The Company announced on 27 June 2019 that one of the Company's borrowers was in the process of undertaking an equity raise or company sale. Whilst this process has been progressing, it was originally hoped that it would conclude in the first quarter of 2020 so as to ensure full repayment of the loan at its face value of £13 million, plus accrued interest. Whilst the Investment Adviser still believes it more likely than not that the equity raise or company sale will conclude, the timeframe for conclusion has become more uncertain owing in part to Covid19. The IFRS 9 general loss reserve has not been adjusted on this loan, including as a result of any Covid-19 impact (it being currently £2 million plus accrued interest). Whilst the indicated valuations of the portfolio company support a full recovery, the borrower has limited liquidity and consequently a further delay could expose the Company to the risk of material loss. In the circumstances, it is possible that the borrower might request the Company to provide additional capital for working capital purposes. The Board continues to monitor this situation closely given the significance of this loan in the overall position of the Company's loan portfolio.

Contact Details:

 

Hadrian's Wall Capital (Investment Adviser)

Ron Miao / Mike Schozer

Telephone 020 3026 8620

 

International Fund Management (Investment Manager)

Chris Hickling

Telephone: 01481 737600

 

Praxis Fund Services Limited (Administrator)

Ben Le Prevost

Telephone: 01481 755524

 

Winterflood Investment Trusts (Corporate Broker)

Neil Morgan

Telephone: 020 3100 0000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVUPUUPAUPUURC
Date   Source Headline
5th Sep 20195:18 pmRNSTransaction in Own Shares
23rd Aug 20195:16 pmRNSNet Asset Value(s)
15th Aug 20199:50 amRNSHolding(s) in Company
1st Aug 20198:00 amRNSTotal Voting Rights
30th Jul 20193:28 pmRNSTransaction in Own Shares
26th Jul 20194:20 pmRNSPortfolio Update
26th Jul 20194:10 pmRNSNet Asset Value(s)
26th Jul 20194:00 pmRNSDividend Declaration
26th Jun 201910:08 amRNSNet Asset Value(s)
28th May 20195:35 pmRNSNet Asset Value(s)
23rd May 20197:00 amRNSPortfolio Update
20th May 20199:41 amRNSHolding(s) in Company
3rd May 20194:50 pmRNSPortfolio Update
3rd May 20194:07 pmRNSDividend Declaration
30th Apr 20191:00 pmRNSNet Asset Value(s)
25th Mar 20193:44 pmRNSHalf-year Report - Replacement for 7787T
22nd Mar 20193:47 pmRNSHalf-year Report
22nd Mar 20193:44 pmRNSHolding(s) in Company
18th Mar 20191:29 pmRNSPortfolio Update
28th Feb 20193:56 pmRNSNet Asset Value(s)
1st Feb 20195:00 pmRNSPortfolio Update
1st Feb 20194:30 pmRNSNet Asset Value(s)
1st Feb 20194:30 pmRNSDividend Declaration
31st Dec 201812:07 pmRNSHolding(s) in Company
31st Dec 20188:00 amRNSTotal Voting Rights
28th Dec 20183:30 pmRNSHolding(s) in Company
27th Dec 201810:06 amRNSHolding(s) in Company
24th Dec 20187:00 amRNSPortfolio Update
21st Dec 20181:54 pmRNSHolding(s) in Company
19th Dec 20185:30 pmRNSHadrian's Wall Secured Investments
19th Dec 20187:02 amRNSC Shares Conversion Results
19th Dec 20187:01 amRNSPortfolio Update
19th Dec 20187:00 amRNSNet Asset Value(s)
13th Dec 20187:00 amRNSIntention to convert C Shares
30th Nov 201811:43 amRNSResult of AGM
27th Nov 20184:57 pmRNSNet Asset Value(s)
13th Nov 20184:24 pmRNSRevolving Credit Facility
30th Oct 20187:00 amRNSAnnual Financial Report and Notice of AGM
22nd Oct 201811:59 amRNSNet Asset Value(s)
22nd Oct 201811:59 amRNSPortfolio Update
19th Oct 20185:07 pmRNSDividend Declaration
26th Sep 20189:15 amRNSNet Asset Value(s)
24th Aug 20184:07 pmRNSNet Asset Value(s)
13th Aug 20181:21 pmRNSHolding(s) in Company
20th Jul 20184:20 pmRNSPortfolio Update
20th Jul 20184:10 pmRNSNet Asset Value(s)
20th Jul 20182:09 pmRNSDividend Declaration
19th Jun 20184:44 pmRNSNet Asset Value(s)
23rd May 20184:54 pmRNSNet Asset Value(s)
30th Apr 20185:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.